Capvaxive

Capvaxive is a vaccine designed to protect against pneumococcal infections. It contains pneumococcal polysaccharides conjugated to CRM197, targeting specific serotypes. This vaccine is administered intramuscularly and is manufactured by Merck Sharp & Dohme B.V.

Capvaxive is used to prevent infections caused by pneumococcal bacteria. It is particularly aimed at serotypes that are not covered by other pneumococcal vaccines. The vaccine works by stimulating the immune system to produce antibodies against these specific serotypes, providing protection against potential infections.

After receiving Capvaxive, some individuals may experience common reactions at the injection site, such as redness, swelling, or pain. Systemic effects might include mild fever, fatigue, or muscle aches. These effects are generally temporary and resolve on their own within a few days.

Before administering Capvaxive, it is important to inform healthcare providers about any allergies, especially to any components of the vaccine. Individuals with a history of severe allergic reactions to previous vaccines should exercise caution. Always follow the advice of a healthcare professional regarding the use of this vaccine.

Capvaxive may interact with other medications or vaccines. It is advisable to discuss any current medications or recent vaccinations with a healthcare provider before receiving Capvaxive. Specific interactions with over-the-counter drugs or herbal supplements should also be considered.